日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Regulatory Requirements for Interchangeable Biosimilar Designation

可互换生物类似药认定的监管要求

Samy, Praveen J; Mouslim, Morgane C; Bennett, Charles L; Trujillo, Antonio J

Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates

探究医疗保险计划对生物类似药采用率的影响

Costin, Jeremy; Mouslim, Morgane C; Socal, Mariana P; Trujillo, Antonio

Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products

生物类似药的可及性评估、临床试验和美国食品药品监督管理局审查

Moore, Thomas J; Mouslim, Morgane C; Blunt, Jenna L; Alexander, G Caleb; Shermock, Kenneth M

Recommendations to the Society for Epidemiologic Research for Further Promoting Diversity and Inclusion at the Annual Meeting and Beyond

向流行病学研究学会提出的关于在年会及其他场合进一步促进多样性和包容性的建议

Zhang, Mingyu; Jarrett, Brooke A; Althoff, Keri N; Burman, Frances S; Camarata, Laura; Coburn, Sally B; Dickerson, Aisha S; Foti, Kathryn; Kaur, Maneet; Leifheit, Kathryn M; Malone, Jowanna; Moore, Ebony A; Mouslim, Morgane C; Prata Menezes, Neia; Robsky, Katherine; Tang, Olive; Wallace, Amelia S; Dean, Lorraine T

Healthcare system distrust and the breast cancer continuum of care

对医疗保健系统的不信任与乳腺癌连续性护理

Mouslim, Morgane C; Johnson, Renee M; Dean, Lorraine T

Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

非格司亭生物类似药的供应情况与非格司亭生物制剂的理赔支付变化及患者自付费用变化之间的关联

Mouslim, Morgane C; Trujillo, Antonio J; Alexander, G Caleb; Segal, Jodi B